This issue of Vital Signs, released on August 23, 2010, provides a strategic analysis of trends in biomarkers for improved and accelerated sepsis treatment. Additionally, a company spotlight is provided for B•R•A•H•M•S, a global biotechnology company committed to improving healthcare through the discovery and development of novel and innovative biomarkers for the diagnosis, treatment, and therapeutic management of severe, life-threatening diseases. Reimbursement and regulatory news from the FDA is also provided for the week of July 26, 2010.
This week's issue:
Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.
Speak directly with our analytics experts for tailored recommendations.
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
This issue of Vital Signs, released on August 23, 2010, provides a strategic analysis of trends in biomarkers for improved and accelerated sepsis treatment. Additionally, a company spotlight is provided for BRAHMS, a global biotechnology company committed to improving healthcare through the discovery and development of novel and innovative biomarkers for the diagnosis, treatment, and therapeutic management of severe, life-threatening diseases. Reimbursement and regulatory news from the FDA is also provided for the week of July 26, 2010.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Industries | Healthcare |
| WIP Number | 9561-00-AC-00-00 |
| Is Prebook | No |
Vital Signs - Biomarkers for Improved and Accelerated Sepsis Treatment: Enabling Clinicians to Definitively Diagnose the Disease, Identify the Causative Agent, and Determine the Appropriate Type and Dosage of Antibiotic
Vital Signs - Biomarkers for Improved and Accelerated Sepsis Treatment: Enabling Clinicians to Definitively Diagnose the Disease, Identify the Causative Agent, and Determine the Appropriate Type and Dosage of Antibiotic
RELEASE DATE
23-Aug-2010
23-Aug-2010
REGION
North America
North America
Deliverable Type
Market Research
Market Research
Research Code: 9561-00-AC-00-00
SKU: HC00601-NA-MR_04074
$1,500.00
In stock
SKU
HC00601-NA-MR_04074